Should NSCLC Patients Receive Immunotherapy 'Indefinitely'?

Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.
Medscape Medical News

source https://www.medscape.com/viewarticle/996496?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension